ROAD TO THE CURE UPDATE MARCH 2018

ICBI UPDATE ON THE ROAD TO THE CURE

PROMISING PRELIMINARY RESULTS FROM TREATMENT OF ALZHEIMER’S AND LEWY BODY PATIENTS WITH AN ANTIBODY DRUG

Debilitation due to neurodegenerative Alzheimer’s (AD) and Parkinson’s (PD) diseases continue to escalate as the diseases progress leaving patients and physicians helpless. According to some studies, more than one billion individuals are globally afflicted with some form of brain disorders. As people are living longer, there is a substantial risk in reaching patients in 2-3 decades. These risks are disproportionally high as patients cannot be successfully cared for by the medical community causing irreparable financial losses to health insurance companies. No one is immune to neurodegeneration. And, all the technological advances of the past century have done very little to treat / or cure brain disorders.   

With no cure on the horizon, a US neurologist is trying an “out of the box” approach to ameliorate the sufferings of his patients. What he found was startling.

He treated Alzheimer and Lewy Body (LB) patients with his antibody drug and found out that this drug significantly improved the cognition of his patients, even though the drug has very little permeability across the blood-brain barrier (BBB) into the central nervous system (CNS).

The neurologist has contacted ICB International, Inc., to transform his drug into a BBB permeable SMART Molecule (SM). This physician believes that his patients could potentially lead symptom-free lives if his drug could reach the brain at a higher dose than what is being administered now.

So, why is there a delay in developing SMART Molecules for this neurologist’s drug?

The answer: 1) the cost of developing the drug; 2) Approval from the neurologist’s hospital to conduct trials when the drug is ready to use in humans in about 15-18 months.

Several of the neurologist’s patients have volunteered to help with the development cost of the SMART Molecule. This drug under consideration is not only good for Alzheimer’s and Lewy Body disease, it should have clinical benefits for all patients whose disease is caused by the aggregated proteins in the brain such as Parkinson’s patients, Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP), and many other patients.